Motley Fool
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
📊
AI Sentiment
Positive
7/10
- Home
- APLS
as of 03-24-2026 3:54pm EST
$17.28
$0.30
-1.68%
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.7B | IPO Year: | 2015 |
| Target Price: | $31.65 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Buy | Number of Analysts: | 21 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.20 | EPS Growth: | 112.50 |
| 52 Week Low/High: | $16.10 - $30.48 | Next Earning Date: | 05-06-2026 |
| Revenue: | $1,003,782,000 | Revenue Growth: | 28.46% |
| Revenue Growth (this year): | -12.44% | Revenue Growth (next year): | 18.21% |
| P/E Ratio: | 86.38 | Index: | N/A |
| Free Cash Flow: | 45.0M | FCF Growth: | N/A |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
DeLong Mark Jeffrey
Sell
Chief Business & Strat Officer
APLS Feb 11, 2026
Avg Cost/Share
$22.15
Shares
368
Total Value
$8,152.56
Owned After
114,591
SEC Form 4
Deschatelets Pascal
Sell
Chief Scientific Officer
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
5,928
Total Value
$129,025.29
Owned After
1,151,382
SEC Form 4
Nicholson Nur
Sell
Chief Technical Officer
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
7,725
Total Value
$168,137.72
Owned After
71,118
SEC Form 4
Sullivan Timothy Eugene
Sell
Chief Financial Officer
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
10,287
Total Value
$223,900.67
Owned After
93,901
SEC Form 4
Watson David O.
Sell
General Counsel
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
7,832
Total Value
$170,466.61
Owned After
88,531
SEC Form 4
Francois Cedric
Sell
Chief Executive Officer
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
27,192
Total Value
$591,844.76
Owned After
286,045
SEC Form 4
Chopas James George
Sell
VP/Chief Accounting Officer
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
2,064
Total Value
$44,923.79
Owned After
49,805
SEC Form 4
DeLong Mark Jeffrey
Sell
Chief Business & Strat Officer
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
3,371
Total Value
$73,371.16
Owned After
114,591
SEC Form 4
Baumal Caroline
Sell
Chief Medical Officer
APLS Jan 22, 2026
Avg Cost/Share
$21.77
Shares
2,797
Total Value
$60,877.82
Owned After
86,527
SEC Form 4
Deschatelets Pascal
Sell
Chief Scientific Officer
APLS Jan 20, 2026
Avg Cost/Share
$19.79
Shares
909
Total Value
$17,991.75
Owned After
1,151,382
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Feb 11, 2026 | Sell | $22.15 | 368 | $8,152.56 | 114,591 | |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Jan 22, 2026 | Sell | $21.77 | 5,928 | $129,025.29 | 1,151,382 | |
| Nicholson Nur | APLS | Chief Technical Officer | Jan 22, 2026 | Sell | $21.77 | 7,725 | $168,137.72 | 71,118 | |
| Sullivan Timothy Eugene | APLS | Chief Financial Officer | Jan 22, 2026 | Sell | $21.77 | 10,287 | $223,900.67 | 93,901 | |
| Watson David O. | APLS | General Counsel | Jan 22, 2026 | Sell | $21.77 | 7,832 | $170,466.61 | 88,531 | |
| Francois Cedric | APLS | Chief Executive Officer | Jan 22, 2026 | Sell | $21.77 | 27,192 | $591,844.76 | 286,045 | |
| Chopas James George | APLS | VP/Chief Accounting Officer | Jan 22, 2026 | Sell | $21.77 | 2,064 | $44,923.79 | 49,805 | |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Jan 22, 2026 | Sell | $21.77 | 3,371 | $73,371.16 | 114,591 | |
| Baumal Caroline | APLS | Chief Medical Officer | Jan 22, 2026 | Sell | $21.77 | 2,797 | $60,877.82 | 86,527 | |
| Deschatelets Pascal | APLS | Chief Scientific Officer | Jan 20, 2026 | Sell | $19.79 | 909 | $17,991.75 | 1,151,382 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-2.30%
$22.67
Act: -8.28%
5D
-6.57%
$21.68
Act: -11.77%
20D
+14.37%
$26.53
Act: -2.67%
Price: $23.20 Prob +5D: 0% AUC: 1.000
0001193125-26-010540
8-K
false 0001492422 0001492422 2026-01-12 2026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026
Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware
001-38276
27-1537290
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Fifth Avenue Waltham, MA
02451
(Address of Principal Executive Offices)
(Zip Code) Registrant’s telephone number, including area code: (617) 977-5700 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per share
APLS
Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 12, 2026, Apellis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing preliminary unaudited total U.S. net product revenues and net product revenues for SYFOVRE and EMPAVELI for the fourth quarter and full year ended December 31, 2025 and its cash and cash equivalents as of December 31, 2025. The full text of the press release issued by the Company in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company’s U.S. net product revenues and cash figures are preliminary and unaudited, represent management’s estimate as of the date of this report and are subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the Company’s net product revenues or cash figures. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press Release dated January 12, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Apellis Pharmaceuticals, Inc.
Date: January 12, 2026
By:
/s/ Timothy Sullivan
Timothy Sullivan
Chief Financial Officer
2024 Q4 Q4 2024 Earnings
8-K Jan 13, 2025
2024
Q4
Q4 2024 Earnings
8-KJan 13, 2025
0001193125-25-005052
8-K
false 0001492422 0001492422 2025-01-08 2025-01-08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025
Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware
001-38276
27-1537290
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Fifth Avenue Waltham, MA
02451
(Address of Principal Executive Offices)
(Zip Code) Registrant’s telephone number, including area code: (617) 977-5700 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
APLS
Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025, Apellis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing preliminary unaudited total U.S. net product revenues and net product revenues for SYFOVRE and EMPAVELI for the fourth quarter and full year ended December 31, 2024 and its cash and cash equivalents as of December 31, 2024. The full text of the press release issued by the Company in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company’s U.S. net product revenues and cash figures are preliminary and unaudited, represent management’s estimate as of the date of this report and are subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the Company’s net product revenues or cash figures. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Keli Walbert to the Board of Directors On January 8, 2025, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, elected Keli Walbert to the Board as a Class II director to serve until the Annual Meeting of Stockholders to be held in 2025 or until her successor has been duly elected and qualified or until her earlier death, resignation or removal. The Board has determined that Ms. Walbert is “independent” as contemplated by the Nasdaq Stock Market rules. Ms. Walbert will be compensated in the same manner as the Company’s other non-employee directors. Information concerning the current compensation of the Company’s directors is set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 26, 2024. Accordingly, upon her election to the Board, Ms. Walbert was granted under the Company’s 2017 Stock Incentive Plan (i) an option to purchase 15,388 shares of the Company’s common stock at an exercise price equal to $33.00 per share, the closing price of the Company’s common stock on the date of grant, which option will vest with respect to one-third of the shares underlying such option on each of the first, second and third anniversaries of the dat
2023 Q4 Q4 2023 Earnings
8-K Feb 27, 2024
2023
Q4
Q4 2023 Earnings
8-KFeb 27, 2024
0001193125-24-047073
8-K
false 0001492422 0001492422 2024-02-27 2024-02-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024
Apellis Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware
001-38276
27-1537290
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
100 Fifth Avenue Waltham, MA
02451
(Address of Principal Executive Offices)
(Zip Code) Registrant’s telephone number, including area code: (617) 977-5700 Not applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
APLS
Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 27, 2024, Apellis Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023 and providing other business updates. The full text of the press release issued by the Company in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 8.01 Other Events.
Capped Call Unwind Agreements On February 27, 2024, the Company entered into agreements with each of Jefferies International Limited and JPMorgan Chase Bank, National Association (collectively, the “Counterparties”) to unwind a portion of the capped call transactions entered into in September 2019 and May 2020 in connection with the issuance of the Company’s 3.500% Senior Convertible Notes due 2026 (the “Notes”). The unwind agreements apply to the portion of the capped call transactions in a notional amount corresponding to the $426.1 million principal amount of Notes that the Company held in treasury as of December 31, 2023 or have been previously converted. The Company expects to receive aggregate cash proceeds from the unwind transactions of approximately $100 million. The unwind transactions will be settled based on the volume-weighted average price of the Company’s common stock over a seven-day averaging period beginning on and including February 27, 2024, and the amount of cash proceeds that the Company receives at the end of the averaging period may be higher or lower than the expected amount. In connection with the unwind, the Counterparties may sell shares of the Company’s common stock in secondary market transactions, and/or unwind various derivative transactions with respect to the common stock.
Forward-Looking Statements
Statements in this Current Report on Form 8-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the settlement of the unwind transactions and the anticipated cash proceeds to the Company from the unwind transactions. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “pro
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
Compare APLS vs Leading Stocks
See how APLS stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.